Prognostic factors and risk stratification in early mycosis fungoides

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 44-50

  Vonderheid, Eric C ^a   Pavlov, Igor ^b   Delgado, Julio C ^b   Martins, Thomas B ^b   Telang, Gladys H ^c   Hess, Allan D ^a   Kadin, Marshall E ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c BROWN UNIVERSITY   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Cytokine production; Lymphoma and Hodgkin disease; Prognostication; T cell mediated immunity

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; IMMUNOGLOBULIN E;

ARTICLE; BASEMENT MEMBRANE; CANCER PROGNOSIS; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DERMIS; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; EOSINOPHIL; GIANT CELL; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ANTIGENS, CD30; BIOLOGICAL MARKERS; DERMIS; DISEASE PROGRESSION; HUMANS; LYMPHOCYTES; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 84891363507     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.790541     Document Type: Article

References (36)

1. Pimpinelli N, Olsen EA, Santucci M, et al. Defi ning early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063.
2. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-Term outcome of 525 patients with mycosis fungoides and S é zary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866.
3. Van Doorn R, Van Haselen CW, Van Voorst Vader PC, et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-510.
4. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/S é zary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.
5. Diamandidou E, Colome M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/S é zary syndrome. J Am Acad Dermatol 1999; 40: 914-924.
6. Jones GW, Wilson LD. The changing survival of patients with mycosis fungoides: A population-based assessment of trends in the United States. Cancer 1999; 86: 191-193.
7. Suzuki SY, Ito K, Ito M, et al. Prognosis of 100 Japanese patients with mycosis fungoides and S é zary syndrome. J Dermatol Sci 2010; 57: 37-43.
8. Talpur R, Singh L, Daulat S, et al. Long-Term outcomes of 1,263 patients with mycosis fungoides and S é zary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051-5060.
9. MartíRM, Estrach T, Reverter JC, et al. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1997; 127: 1511-1516.
10. Hoppe RT, Medeiros LJ, Warnke RA, et al. CD8-positive tumorinfi ltrating lymphocytes influence the long-Term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32: 448-453.
11. Vermeer MH, Van Doorn R, Dukers D, et al. CD8-T cells in cutaneous T-cell lymphoma: Expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-4329.
12. Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009; 33: 1860-1868.
13. Abeni D, Frontani M, Sampogna F, et al. Circulating CD8-lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 2005; 153: 324-330.
14. Tancrède-Bohin E, Ionescu MA, de La Salmonière P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004; 140: 1057-1061.
15. Green SB, Byar DP, Lamberg S I. Prognostic variables in mycosis fungoides. Cancer 1981; 47: 2671-2677.
16. Meissner K, Löning T, Rehpenning W. Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and S é zary syndrome. In Vivo 1993; 7: 277-280.
17. Hallermann C, Niermann C, Fischer RJ, et al. Erythrocyte sedimentation rate as an independent prognostic factor in mycosis fungoides. Br J Dermatol 2012; 166: 873-874.
18. Vonderheid EC, Ekbote SK, Kerrigan K, et al. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. J Invest Dermatol 1998; 110: 946-950.
19. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and S é zary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
20. Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-Term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012; 118: 5830-5839.
21. Kadin ME, Pavlov IY, Delgado JC, et al. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30-cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012; 132: 703-710.
22. Martins TB, Pasi BM, Pickering JW, et al. Determination of cytokine responses using a multiplexed fluorescent microsphere immunoassay. Am J Clin Pathol 2002; 118: 346-353.
23. Wood GS, Abel EA, Hoppe RT, et al. Leu-8 and Leu-9 antigen phenotypes: Immunologic criteria for the distinction of mycosis fungoides from cutaneous infl ammation. J Am Acad Dermatol 1986; 14: 1006-1013.
24. Vonderheid EC, Tan ET, Kantor AF, et al. Long-Term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 416-428.
25. Buhl L, Søgaard H. Immunohistochemical expression of IL-10 in mycosis fungoides. Exp Dermatol 1997; 6: 195-198.
26. Nielsen M, Nissen MH, Gerwien J, et al. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 2002; 99: 973-977.
27. Wood GS, Edinger A, Hoppe RT, et al. Mycosis fungoides skin lesions contain CD8-Tumor-infi ltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. J Cutan Pathol 1994; 21: 151-156.
28. Asadullah K, Friedrich M, Döc ke WD, et al. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-Tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 1997; 108: 743-747.
29. N iX, Hazarika P, Zhang C, et al. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8-cytotoxic T lymphocytes in mycosis fungoides: A potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-2692.
30. Smoller BR, Detwiler SP, Kohler S, et al. Role of histology in providing prognostic information in mycosis fungoides. J Cutan Pathol 1998; 25: 311-315.
31. Schmitt D, Th ivolet J. Lymphocyte-epidermis interactions in malignant epidermotropic lymphomas: I. Ultrastructural aspects. Acta Derm Venereol 1980; 60: 1-11.
32. Edelson RL. Cutaneous T cell lymphoma: The helping hand of dendritic cells. Ann NY Acad Sci 2001; 941: 1-11.
33. Hödl S [Mycosis fungoides and S é zary syndrome. A retrospective study of 60 patients with correlation between histologic classification and survival time.] ZHautkr 1986; 61: 993-1013.
34. Brooks B, Sørensen FB, Th estrup-Pedersen K. Estimates of nuclear volume in plaque and tumor-stage mycosis fungoides. A new prognostic indicator. Am J Dermatopathol 1994; 16: 599-606.
35. Van Vloten WA, Van Duijn P, Schaberg A. Cytodiagnostic use of Feulgen-DNA measurements in cell imprints from the skin of patients with mycosis fungoides. Br J Dermatol 1974; 91: 365-371.
36. Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med 2007; 39: 440-456.